Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487

1.

TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.

Zinnhardt B, Müther M, Roll W, Backhaus P, Jeibmann A, Foray C, Barca C, Döring C, Tavitian B, Dollé F, Weckesser M, Winkeler A, Hermann S, Wagner S, Wiendl H, Stummer W, Jacobs AH, Schäfers M, Grauer OM.

Neuro Oncol. 2020 Feb 12. pii: noaa023. doi: 10.1093/neuonc/noaa023. [Epub ahead of print]

PMID:
32047908
2.

Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS.

Muthuraman M, Fleischer V, Kroth J, Ciolac D, Radetz A, Koirala N, Gonzalez-Escamilla G, Wiendl H, Meuth SG, Zipp F, Groppa S.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(3). pii: e681. doi: 10.1212/NXI.0000000000000681. Print 2020 May 4.

3.

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning.

Arloth J, Eraslan G, Andlauer TFM, Martins J, Iurato S, Kühnel B, Waldenberger M, Frank J, Gold R, Hemmer B, Luessi F, Nischwitz S, Paul F, Wiendl H, Gieger C, Heilmann-Heimbach S, Kacprowski T, Laudes M, Meitinger T, Peters A, Rawal R, Strauch K, Lucae S, Müller-Myhsok B, Rietschel M, Theis FJ, Binder EB, Mueller NS.

PLoS Comput Biol. 2020 Feb 3;16(2):e1007616. doi: 10.1371/journal.pcbi.1007616. eCollection 2020 Feb.

4.

Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.

Heming M, Lohmann L, Schulte-Mecklenbeck A, Brix T, Gross CC, Wiendl H, Klotz L, Meyer Zu Hörste G.

J Neuroimmunol. 2020 Jan 27;341:577171. doi: 10.1016/j.jneuroim.2020.577171. [Epub ahead of print]

5.

Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system.

Backhaus P, Roll W, Beuker C, Zinnhardt B, Seifert R, Wenning C, Eisenblätter M, Thomas C, Schmidt-Pogoda A, Strunk D, Wagner S, Faust A, Tüttelmann F, Röpke A, Jacobs AH, Stummer W, Wiendl H, Meuth SG, Schäfers M, Grauer O, Minnerup J.

Eur J Nucl Med Mol Imaging. 2020 Jan 20. doi: 10.1007/s00259-019-04662-4. [Epub ahead of print]

PMID:
31960097
6.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2020 Jan 18. doi: 10.1007/s00401-019-02107-8. [Epub ahead of print]

PMID:
31955222
7.

Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Feb;16(2):125. doi: 10.1038/s41582-020-0310-1.

PMID:
31937911
8.

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis.

Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, Wolbert J, Heming M, Meuth SG, Kuhlmann T, Gross CC, Wiendl H, Yosef N, Meyer Zu Horste G.

Nat Commun. 2020 Jan 14;11(1):247. doi: 10.1038/s41467-019-14118-w.

9.

An enigmatic case of cortical anopsia: Antemortem diagnosis of a 14-3-3 negative Heidenhain-variant MM1-sCJD.

Obergassel J, Lohmann L, Meuth SG, Wiendl H, Grauer O, Nelke C.

Prion. 2020 Dec;14(1):24-28. doi: 10.1080/19336896.2019.1706703.

10.

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses.

Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG.

J Clin Med. 2019 Dec 22;9(1). pii: E35. doi: 10.3390/jcm9010035.

11.

Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration.

Speicher AM, Wiendl H, Meuth SG, Pawlowski M.

Mol Neurodegener. 2019 Dec 19;14(1):46. doi: 10.1186/s13024-019-0347-z. Review.

12.

CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome.

Gross CC, Meyer C, Bhatia U, Yshii L, Kleffner I, Bauer J, Tröscher AR, Schulte-Mecklenbeck A, Herich S, Schneider-Hohendorf T, Plate H, Kuhlmann T, Schwaninger M, Brück W, Pawlitzki M, Laplaud DA, Loussouarn D, Parratt J, Barnett M, Buckland ME, Hardy TA, Reddel SW, Ringelstein M, Dörr J, Wildemann B, Kraemer M, Lassmann H, Höftberger R, Beltrán E, Dornmair K, Schwab N, Klotz L, Meuth SG, Martin-Blondel G, Wiendl H, Liblau R.

Nat Commun. 2019 Dec 18;10(1):5779. doi: 10.1038/s41467-019-13593-5.

13.

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.

Möhn N, Pfeuffer S, Ruck T, Gross CC, Skripuletz T, Klotz L, Wiendl H, Stangel M, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2). pii: e654. doi: 10.1212/NXI.0000000000000654. Print 2020 Mar.

14.

Serial position effects rapidly distinguish Alzheimer's from frontotemporal dementia.

Kloth N, Lemke J, Wiendl H, Meuth SG, Duning T, Johnen A.

J Neurol. 2019 Dec 5. doi: 10.1007/s00415-019-09662-w. [Epub ahead of print]

PMID:
31807915
15.

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.

Rolfes L, Pawlitzki M, Pfeuffer S, Thomas C, Schmidt-Chanasit J, Gross CC, Schulte-Mecklenbeck A, Wiendl H, Meuth SG, M Grauer O, Ruck T.

Int J Mol Sci. 2019 Nov 28;20(23). pii: E5985. doi: 10.3390/ijms20235985.

16.

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.

Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610. [Epub ahead of print]

PMID:
31762387
17.

Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents.

Schmidt-Pogoda A, Bonberg N, Koecke MHM, Strecker JK, Wellmann J, Bruckmann NM, Beuker C, Schäbitz WR, Meuth SG, Wiendl H, Minnerup H, Minnerup J.

Ann Neurol. 2020 Jan;87(1):40-51. doi: 10.1002/ana.25643. Epub 2019 Nov 26.

PMID:
31714631
18.

[Frequency and risk factors associated with post-stroke dementia-an observational study on stroke patients without premorbid cognitive impairment].

Johnen A, Räthe S, Lohmann H, Philipp K, Minnerup J, Wiendl H, Meuth SG, Duning T.

Nervenarzt. 2020 Feb;91(2):131-140. doi: 10.1007/s00115-019-00830-x. German.

PMID:
31712835
19.

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.

Rolfes L, Pfeuffer S, Ruck T, Windhagen S, Oschlies I, Pavenstädt HJ, Angenendt L, Wiendl H, Krämer J, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1). pii: e638. doi: 10.1212/NXI.0000000000000638. Print 2020 Jan. No abstract available. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2019 Dec 5;7(1):.

20.

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.

Keller CW, Ruck T, McHugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Münz C, Nimmerjahn F, Wiendl H, Lünemann JD.

Ann Clin Transl Neurol. 2019 Dec;6(12):2586-2594. doi: 10.1002/acn3.50935. Epub 2019 Nov 4.

21.

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P.

Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759. [Epub ahead of print]

PMID:
31675266
22.

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.

Wiendl H, Carraro M, Comi G, Izquierdo G, Kim HJ, Sharrack B, Tornatore C, Daizadeh N, Chung L, Jacobs AK, Hogan RJ, Wychowski LV, Van Wijmeersch B; CARE-MS I, CARE-MS II, and CAMMS03409 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 29;7(1). pii: e635. doi: 10.1212/NXI.0000000000000635. Print 2020 Jan.

23.

Resolving the cognitive clinico-radiological paradox - Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis.

Johnen A, Schiffler P, Landmeyer NC, Tenberge JG, Riepl E, Wiendl H, Krämer J, Meuth SG.

Cortex. 2019 Dec;121:239-252. doi: 10.1016/j.cortex.2019.08.022. Epub 2019 Sep 26.

PMID:
31654896
24.

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Jan;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Epub 2019 Oct 24. Review. Erratum in: Nat Rev Neurol. 2020 Feb;16(2):125.

PMID:
31649335
25.

EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases.

von Martial S, Brix TJ, Klotz L, Neuhaus P, Berger K, Warnke C, Meuth SG, Wiendl H, Dugas M.

PLoS One. 2019 Oct 15;14(10):e0223886. doi: 10.1371/journal.pone.0223886. eCollection 2019.

26.

Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke: The Save ChildS Study.

Sporns PB, Sträter R, Minnerup J, Wiendl H, Hanning U, Chapot R, Henkes H, Henkes E, Grams A, Dorn F, Nikoubashman O, Wiesmann M, Bier G, Weber A, Broocks G, Fiehler J, Brehm A, Psychogios M, Kaiser D, Yilmaz U, Morotti A, Marik W, Nolz R, Jensen-Kondering U, Schmitz B, Schob S, Beuing O, Götz F, Trenkler J, Turowski B, Möhlenbruch M, Wendl C, Schramm P, Musolino P, Lee S, Schlamann M, Radbruch A, Rübsamen N, Karch A, Heindel W, Wildgruber M, Kemmling A.

JAMA Neurol. 2019 Oct 14. doi: 10.1001/jamaneurol.2019.3403. [Epub ahead of print]

PMID:
31609380
27.

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?

Pawlitzki M, Schneider-Hohendorf T, Rolfes L, Meuth SG, Wiendl H, Schwab N, Grauer OM.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 9;6(6):e627. doi: 10.1212/NXI.0000000000000627. Print 2019 Nov. No abstract available.

28.

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review.

Rolfes L, Pfeuffer S, Ruck T, Melzer N, Pawlitzki M, Heming M, Brand M, Wiendl H, Meuth SG.

J Clin Med. 2019 Oct 4;8(10). pii: E1623. doi: 10.3390/jcm8101623. Review.

29.

Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis.

Herich S, Schneider-Hohendorf T, Rohlmann A, Khaleghi Ghadiri M, Schulte-Mecklenbeck A, Zondler L, Janoschka C, Ostkamp P, Richter J, Breuer J, Dimitrov S, Rammensee HG, Grauer OM, Klotz L, Gross CC, Stummer W, Missler M, Zarbock A, Vestweber D, Wiendl H, Schwab N.

Brain. 2019 Nov 1;142(11):3411-3427. doi: 10.1093/brain/awz301.

PMID:
31563951
30.

Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis.

Johnen A, Elpers C, Riepl E, Landmeyer NC, Krämer J, Polzer P, Lohmann H, Omran H, Wiendl H, Göbel K, Meuth SG.

Eur J Paediatr Neurol. 2019 Nov;23(6):783-791. doi: 10.1016/j.ejpn.2019.08.007. Epub 2019 Sep 5.

PMID:
31540711
31.

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Willekens B, Presas-Rodríguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, De Laere M, Wens I, Cras P, Parizel P, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye MM, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, Lopez-Diaz de Cerio A, Inogés S, Prosper F, Kip A, Verheij H, Gross CC, Wiendl H, Van Ham MS, Ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z, Martínez-Cáceres E, Cools N, Ramo-Tello C; RESTORE consortium.

BMJ Open. 2019 Sep 9;9(9):e030309. doi: 10.1136/bmjopen-2019-030309.

32.

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. No abstract available.

PMID:
31439633
33.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

34.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Dec;90(12):1245-1253. doi: 10.1007/s00115-019-0760-0. Review. German.

PMID:
31297574
35.

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.

Hundehege P, Cerina M, Eichler S, Thomas C, Herrmann AM, Göbel K, Müntefering T, Fernandez-Orth J, Bock S, Narayanan V, Budde T, Speckmann EJ, Wiendl H, Schubart A, Ruck T, Meuth SG.

Neural Regen Res. 2019 Nov;14(11):1950-1960. doi: 10.4103/1673-5374.259622.

36.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27. Erratum in: Acta Neuropathol. 2020 Jan 18;:.

37.

Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.

Langenbruch L, Krämer J, Güler S, Möddel G, Geßner S, Melzer N, Elger CE, Wiendl H, Budde T, Meuth SG, Kovac S.

J Neurol. 2019 Jul;266(7):1789-1795. doi: 10.1007/s00415-019-09332-x. Epub 2019 May 8.

PMID:
31069528
38.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
39.

Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease.

Schröder JB, Marian T, Claus I, Muhle P, Pawlowski M, Wiendl H, Suntrup-Krueger S, Meuth SG, Dziewas R, Ruck T, Warnecke T.

Front Neurol. 2019 Apr 16;10:386. doi: 10.3389/fneur.2019.00386. eCollection 2019.

40.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
41.

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.

Heming M, Schulte-Mecklenbeck A, Brix T, Wolbert J, Ruland T, Klotz L, Meuth SG, Gross CC, Wiendl H, Meyer Zu Hörste G.

Front Immunol. 2019 Mar 21;10:515. doi: 10.3389/fimmu.2019.00515. eCollection 2019.

42.

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.

Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.

43.

Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis.

Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H.

Neurol Res Int. 2019 Mar 3;2019:1969068. doi: 10.1155/2019/1969068. eCollection 2019.

44.

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis.

Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, Meuth SG, Seebohm G, Melzer N.

Front Neurol. 2019 Mar 1;10:178. doi: 10.3389/fneur.2019.00178. eCollection 2019.

45.

A fatal case of daclizumab-induced liver failure in a patient with MS.

Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, Baba HA, Schulte-Mecklenbeck A, Wiendl H, Kleinschnitz C, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Jan 21;6(2):e539. doi: 10.1212/NXI.0000000000000539. eCollection 2019 Mar. No abstract available.

46.

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells.

Breuer J, Schneider-Hohendorf T, Ostkamp P, Herich S, Rakhade S, Antonijevic I, Klotz L, Wiendl H, Schwab N.

Int Immunol. 2019 May 21;31(6):407-412. doi: 10.1093/intimm/dxz018.

PMID:
30783682
47.

Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke.

Schulte-Mecklenbeck A, Kleffner I, Beuker C, Wirth T, Hartwig M, Schmidt-Pogoda A, Klotz L, Hansen W, Wiendl H, Meuth SG, Gross CC, Minnerup J.

Eur J Neurol. 2019 Jun;26(6):919-926. doi: 10.1111/ene.13909. Epub 2019 Feb 8.

PMID:
30659722
48.

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease.

Schröder JB, Pawlowski M, Meyer Zu Hörste G, Gross CC, Wiendl H, Meuth SG, Ruck T, Warnecke T.

Front Neurol. 2018 Dec 18;9:1081. doi: 10.3389/fneur.2018.01081. eCollection 2018.

49.

Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation.

Schmidt-Pogoda A, Strecker JK, Liebmann M, Massoth C, Beuker C, Hansen U, König S, Albrecht S, Bock S, Breuer J, Sommer C, Schwab N, Wiendl H, Klotz L, Minnerup J.

PLoS One. 2018 Dec 27;13(12):e0209871. doi: 10.1371/journal.pone.0209871. eCollection 2018.

50.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

Supplemental Content

Loading ...
Support Center